Soft Tissue Sarcomas Clinical Trial
Official title:
Phase II Randomized Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas After One Prior Line of Systemic Therapy or Ineligible to Receive an Anthracycline-based Treatment
This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (PFS) at 6 months
The investigators hypothesize that the nivolumab alone or nivolumab plus pazopanib will be
associated with an improvement in progression free survival (PFS) at 6 months compared to
historical controls of placebo and pazopanib alone respectively.
This is a randomized, Phase 2 study of nivolumab alone or nivolumab plus pazopanib in adult
(≥ 18 years old) male and female subjects with unresectable or metastatic soft tissue sarcoma
either ineligible to receive an anthracycline-based first line treatment or after one prior
systemic therapy. Up to 33 and 46 subjects will be randomized (1:1) in the nivolumab and
nivolumab plus pazopanib cohorts respectively, with a Simon two-stage design. Preliminary
endpoint analysis will be performed when at least 18 subjects in the nivolumab cohort and 16
subjects in the nivolumab plus pazopanib cohort, have completed the first 12 cycles of
nivolumab (6 months). Accrual duration is expected to be around 2 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00385203 -
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
|
Phase 2 | |
Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05739084 -
Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS
|
||
Recruiting |
NCT00687778 -
11C-Acetate PET/CT Non-FDG-Avid Tumors
|
N/A | |
Recruiting |
NCT04506008 -
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
|
Phase 2 | |
Terminated |
NCT02575066 -
Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients
|
Phase 2 | |
Completed |
NCT04223583 -
Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
|
Phase 4 | |
Recruiting |
NCT04425967 -
Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas
|
N/A | |
Not yet recruiting |
NCT03946943 -
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
|
Phase 2 | |
Withdrawn |
NCT00881595 -
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00423254 -
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
|
Phase 1 | |
Completed |
NCT00276302 -
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
|
Phase 1 | |
Completed |
NCT01830153 -
RAD001 in Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT02636725 -
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
|
Phase 2 |